Media.Player

1,1-DIOXO-1,2,6-THADIAZINE 2-SUBSTITUTED 5-CARBOXYLATE AND 5-CARBOXAMIDE DERIVATIVES WITH CANNABINOID PROPERTIES

Detailed Technology Description

None

Supplementary Information

Patent Number: WO2007054601A1
Application Number: WO2006ES70172A
Inventor: PAÉZ PROSPER, Juan Antonio | GOYA LAZA, María Pilar | CANO RAMOS, Carolina | MARTÍN FONTELLES, Maria Isabel | GIRÓN MORENO, Maria del Rocío | GOICOECHEA GARCÍA, Carlos
Priority Date: 11 Nov 2005
Priority Number: WO2007054601A1
Application Date: 8 Nov 2006
Publication Date: 18 May 2007
IPC Current: C07D028516 | A61K0031549
Assignee Applicant: Consejo Superior De Investigaciones Científicas | Universidad Rey Juan Carlos
Title: 1,1-DIOXO-1,2,6-THADIAZINE 2-SUBSTITUTED 5-CARBOXYLATE AND 5-CARBOXAMIDE DERIVATIVES WITH CANNABINOID PROPERTIES | DERIVADOS DE 5-CARBOXILATO Y 5-CARBOXAMIDA 2-SUSTITUIDOS DE 1,1-DIOXO-1,2,6-TIADIAZINA CON PROPIEDADES CANNABINOIDES | DERIVES DE 5-CARBOXYL
Usefulness: 1,1-DIOXO-1,2,6-THADIAZINE 2-SUBSTITUTED 5-CARBOXYLATE AND 5-CARBOXAMIDE DERIVATIVES WITH CANNABINOID PROPERTIES | DERIVADOS DE 5-CARBOXILATO Y 5-CARBOXAMIDA 2-SUSTITUIDOS DE 1,1-DIOXO-1,2,6-TIADIAZINA CON PROPIEDADES CANNABINOIDES | DERIVES DE 5-CARBOXYLATE ET 5-CARBOXAMIDE 2-SUBSTITUES DE 1,1-DIOXO-1,2,6-TIADIAZINE PRESENTANT DES PROPRIETES CANNABINOIDES
Summary: (I) Are useful as medicaments for treating disorders involving cannabinoid receptors, specifically for the treatment or prevention of glaucoma, bronchial asthma, chronic bronchitis, allergies (e.g. contact dermatitis or allergic conjunctivitis), arthritis, pain, organ transplantation problems, motor disorders associated with Tourette syndrome, Parkinson's disease, Huntington's chorea, malignant glioma, multiple sclerosis, emesis (and other toxic or undesirable side effects of anticancer chemotherapy), appetite disorders, acute schizophrenia or cognitive and memory disorders associated with Alzheimer's disease. (I) Are also useful for carrying out pharmacological tests for characterization of receptors and confirmation of agonist and antagonist activities (all claimed).
Novelty: New 1,1-dioxo-1,2,6-thiadiazine-5-carboxylic acid derivatives, useful as cannabinoid agonist/antagonist for treating e.g. glaucoma, asthma, allergies, arthritis, pain, emesis or schizophrenia

Industry

Disease Diagnostic/Treatment

Sub Category

Cancer/Tumor

*Abstract

The invention relates to derivatives of 1,1-dioxo-1,2,6-thadiazine-5-carboxamide with chemical structure I and derivatives of 1,1-dioxo-1,2,6-thadiazine-5-alkyl carboxylate with chemical structure II, having cannabinoid properties, wherein: R₁ and R₂, which may be identical or different, are members of the group containing linear or branched alkyl (C1 C7), cycloalkyl (C5-C8), heteroaryl, aryl or aralkyl, in which the phenyl group can contain 1, 2 or 3 substituents from the group containing alkyl, halogen, hydroxy, alkoxy, trifluoromethyl, nitro or amino; R₃ is a member of the group containing hydrogen, linear or branched alkyl (C1-C3); R₄ is a member of the group containing pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, alkylic derivatives of bicyclic[2.2.1]heptyl, linear or branched alkyl (C1 C7), cycloalkyl (C5-C8), heteroaryl, aryl and aralkyl, in which the phenyl group can contain 1, 2 or 3 substituents from the group containing alkyl, hydroxy, nitro, amino or halogen; and X is a member of the group containing hydroxy, linear or branched alkoxy, as well as the organic and inorganic acid salts thereof.

*Principal Investigator

Name: Maria Isabel Martin, Researcher

Department: Health Science III

Country/Region

USA